SCHEMBL14778933

SCHEMBL14778933

COC(=O)c1cncc(-c2ccc3c(n2)CCC(=O)N3)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 4/20 0.48
▸ CYP11B2 P19099 6/20 0.45
▸ CYP11B1 P15538 5/20 0.45
▸ CYP1A2 P05177 1/20 0.42
▸ MTOR P42345 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ CYP2A6 P11509 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ CYP19A1 P11511 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ SPR P35270 1/20 0.38
▸ S1PR1 P21453 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ HPGDS O60760 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ MMP12 P39900 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14779503 0.77 CYP11B2 (0.45) CYP11B2CYP11B1CYP1A2MTORCYP2A6
SCHEMBL14816641 0.77 PRMT5 (0.38) CRBNCYP11B2CYP11B1CYP1A2HTT
SCHEMBL14816637 0.74 CYP11B2 (0.38) CRBNCYP11B2CYP11B1CYP1A2HTT
SCHEMBL14780112 0.73 CYP11B1 (0.59) CYP11B2CYP11B1CYP1A2CYP19A1
SCHEMBL31259930 0.73 CYP11B1 (0.59) CYP11B2CYP11B1CYP1A2CYP19A1
SCHEMBL19542244 0.73 CRBN (0.48) CRBNALOX15HTTHSD17B10ATM
SCHEMBL31225030 0.71 CYP11B2 (0.47) CYP11B2CYP11B1MTORCYP2A6ATM
SCHEMBL31224949 0.71 CYP11B2 (0.52) CYP11B2CYP11B1CYP1A2MTORHSD17B10
SCHEMBL3715051 0.70 ATM (0.69) CYP11B2CYP11B1CYP1A2CYP2A6ATM
SCHEMBL7831294 0.69 CYP11B2 (0.52) CYP11B2CYP11B1MTORCYP2A6ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3653618-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-01-08 — — EP disclosed
EP-3653618-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2020-05-20 — — EP disclosed
EP-3653618-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2020-05-20 — — EP disclosed
EP-2755963-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-10-30 — — EP disclosed
EP-2755963-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-10-30 — — EP disclosed
US-9260408-B2 Dihydroquinoline-2-one derivatives HOFFMANN-LA ROCHE INC. (US) 2016-02-16 — — US disclosed
US-9260408-B2 Dihydroquinoline-2-one derivatives HOFFMANN-LA ROCHE INC. (US) 2016-02-16 — — US disclosed
EP-2755963-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-07-23 — — EP disclosed
WO-2013037779-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-21 — — WO disclosed
WO-2013037779-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-21 — — WO disclosed
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-21 — — US disclosed
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CYP11B1, CYP11B2, HSD11B1 CRBN 2567/4885CYP11B2 2/4885CYP11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback